Gainers

• Polaryx Therapeutics (NASDAQ:PLYX) stock increased by 103.3% to $4.9 during Tuesday's pre-market session. The market value of their outstanding shares is at $114.0 million.
• Masimo (NASDAQ:MASI) stock increased by 34.14% to $174.59. The company's market cap stands at $7.0 billion.
• Compass Pathways (NASDAQ:CMPS) stock rose 18.93% to $6.91. The market value of their outstanding shares is at $543.5 million.
• Ernexa Therapeutics (NASDAQ:ERNA) shares rose 17.77% to $0.38. The company's market cap stands at $2.5 million.
• Alpha Cognition (NASDAQ:ACOG) stock moved upwards by 14.75% to $5.6. The market value of their outstanding shares is at $106.1 million.
• XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 12.11% to $1.0. The market value of their outstanding shares is at $8.4 million.

Losers

• Ocular Therapeutix (NASDAQ:OCUL) shares decreased by 26.9% to $6.49 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.9 billion.
• AIM ImmunoTech (AMEX:AIM) stock declined by 14.4% to $1.07. The company's market cap stands at $4.0 million.
• Picard Medical (AMEX:PMI) shares fell 13.47% to $1.35. The market value of their outstanding shares is at $114.9 million.
• Quince Therapeutics (NASDAQ:QNCX) stock fell 11.26% to $0.18. The market value of their outstanding shares is at $11.1 million.
• SCWorx (NASDAQ:WORX) stock fell 10.85% to $0.25. The company's market cap stands at $4.4 million.
• Strata Skin Sciences (NASDAQ:SSKN) stock fell 10.15% to $0.31. The market value of their outstanding shares is at $2.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.